The government's scientific groups are deliberating on the need for booster dose of COVID-19 and they are reviewing all data from across the world as well as from India, officials said on Friday.
Addressing a press conference, ICMR Director General Balram Bhargava said discussions are going on to look at different aspects of booster dose.
"There is a COVID working group, which has debated on it several times that those recommendations to the subcommittee of the National Technical Advisory Group of immunisation following which it goes to the main technical advisory group of immunisation and then to NEGVAC which will then be accepted by the Ministry of Health," he said.
"So, deliberations are going on and we are reviewing all the scientific data from across the world as well as from India. We are deliberating and we are formulating our policy," he said.
Union Health Secretary Rajesh Bhushan said the government has very clearly articulated the position that it would be governed by science and scientific evidence on deciding on the need and timing for additional doses and for lowering the age of vaccination.
"So our stand remains the same. And when we say science and scientific evidence, I did refer to certain aspects of science and scientific evidence. One aspect relates to antibody titers and their behaviour over a period of time. The other aspect relates to T cells and their behaviour over a period of time," Bhushan said.
"The third aspect relates to hybrid immunity, where you take one dose of vaccination and then get afflicted by the disease, then recover then take the second dose. So these are issues that men of science are deliberating," he said.
Quoting WHO Director-General Tedros Adhanom Ghebreyesus, Bhushan said, "No country can boost its way out of the pandemic and boosters cannot be seen as a ticket to go ahead with planned celebrations without the need for other precautions".
According to WHO expert Abdi Mahamud, Bhushan said, "Although we are seeing a reduction in the neutralization antibodies, almost all data shows T-cells remain intact, that is what we really require."
"While the antibody defences from some courses have been undermined, there has been hope that T-cells, the second pillar of an immune response, can prevent severe disease by attacking infected human cells," Mahamud was quoted as saying by Bhushan.
National Expert Group on vaccine administration for Covid (NEGVAC) and National Technical Advisory Group on Immunization (NTAGI) are deliberating and considering scientific evidence related to justification for booster dose against Covid, the Centre informed Parliament recently.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)